SERIES 6: THE INNOVATION–IMPACT GAP
Series 6: The INNOVATION–IMPACT GAP
AUTHOR: KJ Lavan
WHAT Happens When Science Advances Faster Than the SYSTEM?
For decades, Alzheimer’s disease was described as a scientific problem:
We needed better biomarkers.
Earlier diagnosis.
Disease-modifying therapies.
More precise risk prediction.
Now those advances are arriving.
Lecanemab and donanemab have established that Alzheimer’s pathology can be therapeutically targeted in people with early disease although treatment benefits are measured in slowing progression, not curing or reversing dementia.
Treatment also requires careful patient selection, intravenous administration, specialist oversight, and monitoring for amyloid-related imaging abnormalities.
In May 2025, the FDA cleared the first blood test to assist in diagnosing Alzheimer’s disease. The Lumipulse test measures the plasma ratio of p-tau217 to amyloid-beta 1-42 in symptomatic adults aged 55 and older—potentially reducing reliance on PET imaging and cerebrospinal-fluid testing for many patients. (U.S. Food and Drug Administration)
Research is already moving beyond conventional blood draws.
Recent studies suggest that capillary and dried-blood-spot biomarkers could eventually support decentralized triage, remote collection, clinical-trial recruitment, and broader access outside specialist centers. (Nature)
This is extraordinary scientific progress.
But it exposes a deeper problem:
What happens when innovation becomes scalable but the systems surrounding it do not?
A blood test can identify more people.
But who explains the result?
Who confirms the diagnosis?
Who determines treatment eligibility?
Where are the neurologists, memory clinics, infusion centers, MRI capacity, genetic counseling, longitudinal monitoring, and caregiver-support pathways required afterward?
What happens in communities where primary-care systems are already overloaded?
What happens in countries where advanced imaging, specialists, reimbursement, and treatment infrastructure barely exist?
And what happens when millions of people can finally learn that they have Alzheimer’s pathology
but cannot access meaningful intervention?
This is the emerging Innovation–Impact Gap:
The distance between what science makes possible and what institutions can deliver equitably, safely, and at population scale.
The next Alzheimer’s breakthrough will not be defined only by the sensitivity of a biomarker or the efficacy of a therapy.
It will be defined by whether the surrounding system can absorb it.
That means connecting:
Diagnostics → care pathways
Biomarkers → clinical capacity
Therapeutics → monitoring infrastructure
Risk detection → prevention services
Scientific evidence → financing and reimbursement
Innovation → equitable population impact
Researchers are now explicitly calling for primary-care-centered and scalable models capable of integrating blood biomarkers and disease-modifying therapies into routine care. (PMC)
Because a breakthrough that reaches only those living near advanced medical centers is not yet transformation.
It is concentrated innovation.
The central question is no longer simply:
Can we detect and treat Alzheimer’s disease earlier?
It is:
Can we redesign health, workforce, community, data, and financing systems quickly enough to convert earlier detection into scalable human impact?
Science may be entering a new era.
But scientific innovation without systems innovation will widen the very disparities it was expected to solve.
The future of brain health will not be determined by discovery alone.
It will be determined by absorption capacity.
And that is why cognitive resilience must be built not merely as a medical service.
But, as economic and societal infrastructure.
AUTHOR: KJ Lavan
#Brain Matrix Alliance
#World Health Organization
#Alzheimer's Disease International
Comments
Post a Comment